07-08-2026 21:55 via medpagetoday.com

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...
Read more »

Medical Industry news



FDA Approves First CELMoD Drug for Multiple Myeloma
Luigi Mangione Expected to Plead Guilty in UnitedHealthcare CEO Killing, Source Says
Preoperative GLP-1s Don't Diminish Bariatric Surgery Results, Study Suggests
Researchers Try to Tie Cannabis to Irregular Heartbeats, Opposite Turns Out True
JAK Inhibitor Might Be the Most Effective One Yet for Severe Alopecia
Study Questions How Prostate Cancer Focal Therapy Is Being Used
Trump's Vaccine Order Will Show Up in My ICU
Are HYROX Athletes Overdoing It?
How Much Liquid Is Really in Vaccines? Kinda Chic to get a Colonoscopy; PPE Comeback
Brad Pitt Opens Up About Suicidal Ideation
Tylenol Poisonings; Comedy Therapy Before Liver Transplant? U.S. IBD Prevalence
Trump's Vaccine Plan Brings Obstacles to Parents, Providers, and Drugmakers
Trump's MMR Vaccine Plan Brings Obstacles to Parents, Providers, and Drugmakers
Nurses Sue Managers Over Attacks; Sleep Study Fraud; Spine Device Exec Sentenced
Desktop versie